← Leaderboards
Stephen Richardson
New York University School Of Medicine
$105,030
Attributed
$105,030
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$105,030 · 6
By mechanism
M01$105,030 · 6
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- George G Holz$7,757,380
- Geoffrey C Gurtner$18,025,276
- Hersh Chandarana$4,318,399
- Eric Edward Sigmund$3,337,106
- Gabrielle Gold-Von Simson$641,359
Others in their field
Top investigators on “Diabetes Mellitus Therapy”
- David M Nathan · Massachusetts Institute Of Technology$140,313,171
- John M Lachin · George Washington University$134,552,372
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$126,225,488
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Rose A Gubitosi-Klug · Case Western Reserve University$64,112,836
- David Heimbrook · Leidos Biomedical Research, Inc.$56,712,245
Research focus
Diabetes Mellitus TherapyClinical ResearchNoninsulin Dependent Diabetes MellitusHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationHypoglycemic AgentsInsulinCombination ChemotherapyGlyburideLeptinObesityAminoguanidineAntihyperlipoproteinemic AgentBlood ChemistryBody CompositionBody WeightDiabetic NephropathyDiet TherapyDrug Adverse EffectFastingKidney Disorder ChemotherapyMethionineNutrition Related Tag
Grant awards (22)
PIMAGEDINE IN PATIENTS WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$0
M01 · FY2002 · RR
HOE 902 INSULIN COMPARED TO HUMAN NPH IN TYPE II DIABETES$0
M01 · FY2002 · RR
BRL 49653C QD OR BID + GLYBURIDE IN NON INSULIN DEPENDENT DIABETICS$0
M01 · FY2002 · RR
BRL 49653C GIVEN TO PATIENTS WITH NIDDM INADEQUATELY CONTROLLED ON GLYBURIDE$0
M01 · FY2002 · RR
SQ METHULEPTIN IN OBESE SUBJECTS W/ DIET TREATED NON INSULIN DEPENDEN$0
M01 · FY2002 · RR
SQ METHULEPTIN IN OBESE SUBJECTS W/ DIET TREATED NON INSULIN DEPENDEN$0
M01 · FY2001 · RR
BRL 49653C QD OR BID + GLYBURIDE IN NON INSULIN DEPENDENT DIABETICS$0
M01 · FY2001 · RR
PIMAGEDINE IN PATIENTS WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$0
M01 · FY2001 · RR
BRL 49653C GIVEN TO PATIENTS WITH NIDDM INADEQUATELY CONTROLLED ON GLYBURIDE$0
M01 · FY2001 · RR
HOE 902 INSULIN COMPARED TO HUMAN NPH IN TYPE II DIABETES$0
M01 · FY2001 · RR
PIMAGEDINE IN PATIENTS WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$21,006
M01 · FY2000 · RR
BRL 49653C GIVEN TO PATIENTS WITH NIDDM INADEQUATELY CONTROLLED ON GLYBURIDE$21,006
M01 · FY2000 · RR
HOE 902 INSULIN COMPARED TO HUMAN NPH IN TYPE II DIABETES$21,006
M01 · FY2000 · RR
BRL 49653C QD OR BID + GLYBURIDE IN NON INSULIN DEPENDENT DIABETICS$21,006
M01 · FY2000 · RR
SQ METHULEPTIN IN OBESE SUBJECTS W/ DIET TREATED NON INSULIN DEPENDEN$21,006
M01 · FY2000 · RR
A 100 ON GLYCEMIC CONTROL IN OVERWEIGHT TYPE 2 DIABETIC SUBJECTS WITH INSULIN$0
M01 · FY2000 · RR
A 100 ON GLYCEMIC CONTROL IN OVERWEIGHT TYPE 2 DIABETIC SUBJECTS WITH INSULIN$0
M01 · FY2000 · RR
SQ METHULEPTIN IN OBESE SUBJECTS W/ DIET TREATED NON INSULIN DEPENDEN$0
M01 · FY2000 · RR
BRL 49653C QD OR BID + GLYBURIDE IN NON INSULIN DEPENDENT DIABETICS$0
M01 · FY2000 · RR
HOE 902 INSULIN COMPARED TO HUMAN NPH IN TYPE II DIABETES$0
M01 · FY2000 · RR
BRL 49653C GIVEN TO PATIENTS WITH NIDDM INADEQUATELY CONTROLLED ON GLYBURIDE$0
M01 · FY2000 · RR
PIMAGEDINE IN PATIENTS WITH TYPE II DIABETES AND OVERT DIABETIC NEPHROPATHY$0
M01 · FY2000 · RR